- Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies2021 | Second Faculty of Medicine
- Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group2022 | Second Faculty of Medicine
- Management of patients with intermediate-risk early stage cervical cancer2020 | First Faculty of Medicine
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publication without faculty affiliation
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publication without faculty affiliation
- Early-stage intermediate-risk-the group with the most heterogenous management among patients with cervical cancer2022 | First Faculty of Medicine
- Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes2021 | Third Faculty of Medicine, Central Library of Charles University
- Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission2018 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- 5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer-A Retrospective Analysis2023 | First Faculty of Medicine
- PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer2020 | First Faculty of Medicine
- Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial2007 | Second Faculty of Medicine
- Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease2021 | Publication without faculty affiliation
- Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke2019 | Third Faculty of Medicine
- CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)2022 | First Faculty of Medicine, Faculty of Arts
- Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature2018 | First Faculty of Medicine
- Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group2013 | Second Faculty of Medicine
- A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial)2020 | First Faculty of Medicine
- Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results2013 | First Faculty of Medicine, Second Faculty of Medicine
- Multi-parametric functional hemodynamic optimization improves postsurgical outcome after intermediate risk open gastrointestinal surgery, a randomized controlled trial2019 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- MINIMALLY INVASIVE PELVIC LYMPHADENECTOMY DURING RADICAL PROSTATECTOMY - SINGLE SURGEON TECHNIQUE EVOLUTION IN MULTICENTER SETTINGPublication without faculty affiliation
- Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?2018 | First Faculty of Medicine, Second Faculty of Medicine
- De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors2024 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Central Library of Charles University
- Report of University Hospital Hradec Králové to the clinical trial protocol No: 20090160-21010Publication without faculty affiliation
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia2012 | First Faculty of Medicine
- Radiotherapy in the treatment of epithelial ovarian cancer2003 | First Faculty of Medicine
- Transcatheter aortic valve implantation in patient with cardiogenic shock2018 | Publication without faculty affiliation
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study2015 | First Faculty of Medicine